Patents Assigned to CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
  • Pyrimidine compound acting on EGFR and ERBB2
    Patent number: 11530196
    Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: December 20, 2022
    Assignee: CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
    Inventors: Charles Z. Ding, Lu Zhang, Xile Liu, Lihong Hu, Wen Jiang, Jian Li, Shuhui Chen
  • Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity
    Patent number: 11155559
    Abstract: Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 26, 2021
    Assignee: CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
    Inventors: Yuanshan Yao, Li Zhang, Zhaoguo Chen, Lele Zhao, Lingyun Wu, Shuhui Chen